Linked Life Data

19920112

Source:http://linkedlifedata.com/resource/pubmed/id/19920112

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2009-12-2
pubmed:abstractText
Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer. Among patients who initially respond to trastuzumab therapy, resistance typically arises within 1 year. BT/Her(R) cells are trastuzumab-resistant variants of Her2-positive BT474 breast cancer cells. The salient feature of BT/Her(R) cells is failure to downregulate phosphoinositide 3-kinase/Akt signaling on trastuzumab binding. The current work addresses the mechanism of sustained signaling in BT/Her(R) cells, focusing on the protein kinase A (PKA) pathway.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7196-206
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19920112-Antibodies, Monoclonal, pubmed-meshheading:19920112-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19920112-Antineoplastic Agents, pubmed-meshheading:19920112-Breast Neoplasms, pubmed-meshheading:19920112-Cell Line, Tumor, pubmed-meshheading:19920112-Cyclic AMP, pubmed-meshheading:19920112-Cyclic AMP-Dependent Protein Kinases, pubmed-meshheading:19920112-Drug Resistance, Neoplasm, pubmed-meshheading:19920112-Enzyme Activation, pubmed-meshheading:19920112-Humans, pubmed-meshheading:19920112-Phosphorylation, pubmed-meshheading:19920112-Protein Binding, pubmed-meshheading:19920112-RNA, Small Interfering, pubmed-meshheading:19920112-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19920112-Signal Transduction, pubmed-meshheading:19920112-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.
pubmed:affiliation
Division of Tumor Cell Biology, City of Hope Comprehensive Cancer Center, Duarte, California 91107, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural